rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALKS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
      Nov 16Yahoo FinanceALKS
      Alkermes and Teva reach settlement on LYBALVI patent litigation
      Nov 12Investing.comALKS
      Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
      Nov 5Yahoo FinanceALKS
      H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress
      Nov 4Investing.comALKS
      Wells Fargo raises Alkermes stock price target on sleep drug potential
      Nov 4Investing.comALKS
      Baird reiterates Alkermes stock rating on solid quarterly results
      Nov 4Investing.comALKS
      Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
      Nov 4Yahoo FinanceALKS
      Alkermes to Present at Upcoming Investor Conferences
      Nov 3Yahoo FinanceALKS
      What Alkermes (ALKS) Said on Its Q3 Earnings Call
      Nov 3Yahoo FinanceALKS
      Alkermes plc Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceALKS
      Alkermes Q3 2026 slides: revenue jumps 22% as profits decline
      Nov 3Investing.comALKS
      Alkermes Q3 2026 Earnings Call Transcript
      Nov 3BenzingaALKS
      Earnings call transcript: Alkermes beats Q3 2026 estimates as sales rise
      Nov 3Investing.comALKS
      Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 3Yahoo FinanceALKS
      Alkermes Plc earnings beat by $0.17, revenue topped estimates
      Nov 3Investing.comALKS
      Alkermes Q3 Earnings Fall, Revenue Rises; Reiterates 2026 Revenue Guidance
      Nov 3Yahoo FinanceALKS
      Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
      Nov 3Yahoo FinanceALKS
      Alkermes set to report earnings amid orexin drug pipeline push
      Nov 2Investing.comALKS
      Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?
      Oct 31Yahoo FinanceALKS
      Alkermes begins phase 2 trial of depression treatment candidate
      Oct 30Investing.comALKS
      Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
      Oct 30Yahoo FinanceALKS
      Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story

      Alkermes is rated Buy as LUMRYZ momentum, LYBALVI trends, and pipeline progress drive growth despite near-term profit pressure. Click for more on ALKS stock.

      Oct 29Seeking AlphaALKS
      Alkermes to Report Third Quarter Financial Results on November 3, 2026
      Oct 20Yahoo FinanceALKS
      Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
      Oct 20Yahoo FinanceALKS
      Alkermes stock reinstated Buy at Truist (ALKS:NASDAQ)
      Oct 16Seeking AlphaALKSTFC
      Alkermes to present sleep medicine data at European congress
      Oct 13Investing.comALKS
      Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
      Oct 13Yahoo FinanceALKS
      Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailALKS
      Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity?
      Oct 9Yahoo FinanceALKS
      Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)

      Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp rebound in the broader equity market during the second quarter of 2026, as improving corporate earnings, resilient economic growth, moderating inflation, and continued artificial intelligence […]

      Oct 5Yahoo FinanceALKS
      Stifel reiterates Alkermes stock rating on pipeline confidence
      Oct 5Investing.comALKS
      Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

      Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]

      Sep 26Yahoo FinanceALKS
      Goldman Sachs resumes Alkermes stock coverage with neutral rating
      Sep 24Investing.comALKS
      Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)
      Sep 23Seeking AlphaALKSTAK
      Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

      In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...

      Sep 23Yahoo FinanceALKS
      Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

      ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

      Sep 22Yahoo FinanceALKS
      Exclusive BAC Article: Alkermes; Positive Phase 1b POC Data ALKS 7290 ADHD, Phase 2 Data 2027, Ongoing Phase 3 Alixorexton Studies, And Catalysts (NASDAQ:ALKS)
      Sep 21Seeking AlphaALKS
      Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

      Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.

      Sep 21BenzingaALKS
      TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data
      Sep 21Investing.comALKS
      Stifel reiterates Alkermes stock rating on ADHD drug trial data
      Sep 21Investing.comALKS
      What This Biotech Learned From Narcolepsy And Took To ADHD

      Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

      Sep 21Investor's Business DailyALKS
      Alkermes rises on phase 1 results for ADHD drug ALKS 7290
      Sep 21Seeking AlphaALKS
      Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290

      Alkermes plc (NASDAQ:ALKS) shares gained 6. 5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD).

      Sep 21Yahoo FinanceALKS
      Why is Alkermes stock surging today?
      Sep 21Investing.comALKS
      Alkermes stock jumps on positive ADHD drug trial results
      Sep 21Investing.comALKS
      Alkermes reports positive phase 1 data for ADHD drug candidate
      Sep 21Investing.comALKS
      Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
      Sep 21Yahoo FinanceALKS
      Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell
      Sep 21Yahoo FinanceALKS
      Alkermes slides 7%, reaching multi-month low (ALKS:NASDAQ)

      ALKS stock slid 7% to a June low as healthcare peers fell.

      Sep 18Seeking AlphaALKS
      Alkermes Strengthens Board with New Director Appointment

      Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailALKS

      This is the newest page. Registered accounts read further back.